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ABSTRACT 
         Autoimmunity develops over an extended period of time as the result of an 
amalgamation of genetic, environmental, and immunologic events. Though the precise 
etiological factors leading to most autoimmune disease are awaiting consensus, a 
common thread of the autoimmune paradigm is the inappropriate activation of tissue-
specific immune cells by one or more autoantigen, which begins the destruction of the 
tissue. To prohibit immunopathology and fine-tune the immune responses in healthy 
individuals, the stimulatory activities of effector/memory T (Teffs) cells must be 
counteracted by the suppressive mechanisms of regulatory T cells (Tregs). Thus, the 
potential to modulate the ratio between Teff and Tregs in autoimmune patients has been 
widely investigated with high hopes to permanently cure certain autoimmune diseases 
such as type 1 diabetes militus (T1D). Autoantigen therapies, which attempt to induce 
Tregs to suppress pathogenic effector cells in an autoantigen-specific manner, have 
shown efficacy in preventing T1D in mice, but have largely failed in clinical trials. One 
approach to improve the effectiveness of islet autoantigen vaccinations is to combine 
them with an additional modulator of the T cell response which favors a regulatory 
  vii 
phenotype. In the work presented here, we asked whether the addition of anti-interleukin-
7 receptor-alpha (anti-IL-7Rα) monoclonal antibodies (mAbs) to islet autoantigen 
immunizations would modulate the T cell response and prevent T1D in non-obese 
diabetic (NOD) mice. It was found that anti-IL-7Rα mAbs reduced the absolute numbers 
of islet antigen-specific T cells when immunized with islet peptide in conjunction with 
the commonly used vaccine adjuvant alum. Such treatments were also observed to 
increase nonspecific IL-2, IFN-!, and IL-10 cytokine production, resulting in no 
improvement of T1D onset prevention. In another approach, we generated a conjugate 
vaccine by conjugating islet autoantigens to the immunogenic carrier protein, Keyhole 
Limpet Hemocyanin (KLH). We found that islet antigen-KLH (Ag-KLH) vaccination 
resulted in significant expansion of the desirable antigen-specific Tregs. Further, Ag-
KLH immunization successfully delayed, and in some cases entirely prevented, T1D 
onset in NOD mice. Indicating that KLH-conjugated vaccine may represent a promising 
approach for future autoantigen therapies against autoimmunity. Interestingly, 
administration of anti-IL-7Rα mAbs did not improve these outcomes. To the contrary, we 
again observed excessive nonspecific cytokine production induced by IL-7Rα blockade 
that inhibited the beneficial effects of Ag-KLH vaccination. Taken together, we 
concluded that the addition of anti-IL-7Rα mAbs did not improve the efficacy of 
autoantigen vaccinations to prevent T1D. Significant work still remains to better 
characterize and isolate the beneficial effects of anti-IL-7Rα mAbs to treat autoimmunity. 
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CHAPTER 1: INTRODUCTION 
1.1 Autoimmune Diseases 
 The immune system of vertebrates has the ability to recognize and defend against 
infectious agents in a pathogen-specific manner thanks to the evolutionary onset of the 
adaptive immune response. The other half of the immune response, innate immunity, is 
utilized in both vertebrates and invertebrates alike. However, the protections against the 
free growth of microorganisms that nonspecific innate immunity affords also generate 
pressures for pathogens to evolve mechanisms to evade it. Mycobacterium tuberculosis 
replicates intracellularly to avoid complement-cascades. The entire genus of Salmonella 
makes use of protective capsules which inhibit lysis by complement and phagocytic cells 
of the innate immune response (Finlay B B et al. 1997). Salmonella typhi generates Vi 
antigen, which directly inhibits complement activity (Looney R J et al. 1986). 
Histoplasma capsulatum, a fungus largely found in river basins worldwide, will allow 
itself to be phagocytosed by alveolar macrophages only to survive, germinate, and 
proliferate within the phagosomes of the phagocytes that had tried to consume them 
(Berkes Charlotte et al. 2013). Such evasion strategies are remarkably diverse and can 
often be highly pathogen-specific. In order to survive, many organisms required a system 
of recognizing pathogens, inhibiting or eliminating their mechanisms of defense, and 
developing an immunologic memory to respond to repeated infections in a pathogen-
specific manner. 
The adaptive immune response is induced by the presence of antigens, any small 
molecules or molecular fragments that bind to either extracellular immunoglobulin 
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proteins (antibodies) or to receptors on the surfaces of lymphocytes, known as B cell and 
T cell receptors (BCR and TCR). Lymphocytes (B cells and T cells) in adaptive 
immunity, use these antigens to initiate a coordinated and highly-specific immune 
response against cells expressing (or presenting) the antigen. However, the ability of 
lymphocytes to recognize antigen, but not induce an immune response against it 
(immunologic tolerance) is a fundamental requirement for the functioning of adaptive 
immunity. Organisms must defend themselves from attackers that escape the innate 
response, while disallowing severe collateral damage of their own tissues. Lymphocytes 
have evolved to distinguish between noninfectious ‘self’ and infectious ‘non-self’, often 
referred to as allorecognition, in order to initiate the specific destruction of deleterious 
pathogens while maintaining as much functional tissue as possible (Janeway C A 1992). 
Both B and T cells have multiple anatomical checkpoints at which auto-reactive cells can 
be aborted via a series of mechanisms including clonal deletion, anergy, receptor editing, 
ignorance, and regulation by suppressive cell types (Eisenberg Robert 2005). Serious 
defects at a single stage of the series (Cohen P L et al. 1991), or a moderately increased 
probability of failure at multiple stages (Wakeland E K et al. 2001), will likely result in 
autoimmune disease.   
Autoimmunity often develops over an extended period of time as the result of an 
amalgamation of genetic, environmental, and immunologic events (Dooms Hans 2013). 
The etiology of most autoimmune diseases are still hotly debated. For example, studies of 
type 1 diabetes have suggested a genetic factor in the onset of autoimmunity due to 
higher frequencies of disease occurrence among monozygotic twins (Kaprio J et al. 
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1992). However, investigations into the geographic distribution of type 1 diabetes has 
revealed a 15-fold difference in disease occurrence between Caucasians in Europe, 
strongly suggesting an environmental risk factor (Knip Mikael et al. 2005). Though the 
precise etiological factors leading to most autoimmune disease are awaiting consensus, a 
common thread of the autoimmune paradigm is the inappropriate activation of tissue-
specific immune cells by one or more autoantigen, which begins the destruction of the 
tissue (Fig. 1.1) (Rosenblum Michael D et al. 2015), (Dooms Hans  2013).  
  
Figure 1.1: Common Threads of Autoimmune Diseases. Figure displays some of the general principles 
that lead to autoimmunity. (Top) Relatively few examples of polymorphisms in immune-related alleles 
(HLA, cytokine/receptor pathways, and central tolerance genes such as AIRE) that generate a genetic 
predisposition to autoimmunity. (Left) Examples of environmental triggers of autoimmune diseases 
(infection, microbiome conditions, tissue injuries that result in immunologic insult). (Bottom) Deficits in 
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Treg function leading to dysfunctions in immunologic tolerance. Each of these factors may act alone or in 
combination to allow autoreactive T cells to escape regulation, become activated, proliferate, and damage 
potentially healthy tissue. Figure is adapted from Rosenblum Michael D et al. 2015.   
 
1.2 Type-1-Diabetes 
Type 1 diabetes (T1D), sometimes referred to as insulin dependent diabetes 
melitus (IDDM), is an autoimmune disease characterized by a deficiency in insulin 
production, without which uptake of glucose by cells in the body is severely inhibited. 
Thus, patients diagnosed with T1D require daily administration of insulin in order to 
support their metabolism. Largely as a result of blood sugar increases due to islet 
destruction, type 1 diabetes renders patients susceptible to a plethora of secondary organ 
complications including eye disease (diabetic retinopathy), nerve damage (diabetic 
neuropathy), kidney disease (diabetic nephropathy), as well as cardiovascular diseases 
such as heart disease and stroke. The precise causes of this autoimmune disease are not 
well understood, despite large gains in this immense field of investigation.  
Numerous studies investigating the genetic risk factors of the disease have 
identified more than 50 associated genes with highly variable frequencies among T1D 
patients. Twin studies have revealed that the concordance rates for type 1 diabetes are 
higher in monozygotic twins than that of their dizygotic counterparts (Kaprio J et al. 
1992), which is consistent with a genetic factor determining T1D onset. However, ~50% 
of monozygotic twins are type 1 diabetes discordant, which is strong evidence for a non-
genetically determined factor influencing disease susceptibility (Metcalfe K A et al. 
2001). Also, as mentioned previously, studies of the geographic differences in T1D 
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incidences have shown up to a 15-fold difference between Caucasians living in various 
parts of Europe (Knip Mikael et al. 2005). These findings, among other such 
discrepancies, have led many to conclude that type 1 diabetes is caused by a largely 
unknown mix of genetic and exogenous factors. 
It is known, however, that T1D arises from the autoimmune annihilation of 
insulin-producing B cells. It is widely accepted that clinical onset of T1D begins when 
more than 80% of  B cells within islets of Langerhan have been destroyed (Eizirik Décio 
L et al. 2009). However, questions have been raised as to whether such severe B cell loss 
is required to predict the onset of T1D (Klinke David J  2008). Nonetheless, there are few 
disagreements about the overall importance of B cell elimination in the autoimmune 
cascade leading to disease onset. 
It has long been accepted that type 1 diabetes is an autoimmune disease associated 
with the activation of CD4+ and CD8+ T cells (Roep B O  1996). These autoreactive T 
cells target islet autoantigen epitopes and are considered the mediators of islet B cell 
damage (Roep Bart O  2003). Evidence for such an idea had first come from the 
histological analysis of pancreata from newly-diagnosed type 1 diabetic patients (Gepts 
W  1965), which had revealed inflammatory lesions (insulitis) within the insulin-
producing islets of Langerhan. These lesions were shown to be consistently populated by 
T cells (Fig. 1.2). Further evidence was produced upon discovery that 
immunosuppressive drugs, including those specifically targeting T cells, delayed 
progression of the disease (Bougneres P F et al. 1988).    
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Figure 1.2: Insulitis in islet of Langerhan. Figure displays insulitic pancreas tissue collected from a 
diabetes-induced rat (left) as well as that of a healthy control rat (right). Pancreas tissues were stained for 
DNA (blue), insulin (green), and CD8 (red). Arrows indicate CD8+ T cells. Scale bars 50 µm. Figure is 
adapted from Roberts Frederick R et al. 2017. 
 
1.3 T Regulatory Cells  
It is well known that the thymus, a small gland under the breastbone in the chest, 
is involved in a number of roles crucial for the proper functioning of both adaptive and 
innate immunity. Perhaps the most essential of these functions is to provide an inductive 
environment for hematopoietic progenitor cells to develop and mature into functonal non-
self reactive T cells. Since their discovery in 1968 (Miller J F et al. 1968), the study of T 
cells has become an immense field with continuing heated debates as to the precise 
mechanisms of action and functional motifs of each T cell type and as to the actual 
existence of certain subtypes. Contentious debates aside, hardly a paper in immunology 
since their discovery has been published without at least one mention of the T cell.     
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T cells are one of two primary lymphocytes, the other being B cells which are the 
most salient cell type of humoral immunity. While antibody-producing B cells govern 
humoral immune function, T cells are regarded as the central figures in cell-mediated 
immunity. These cells can vary greatly in their functionality, with roles spanning the 
innate and adaptive immune responses. T cells are generally divided between four cell 
types. T helper cells (TH cells) assist other lymphocytes during the immune responses, 
including facilitating B cell maturation and activation of CD8+ cytotoxic T cells and 
macrophages (Alberts Bruce et al. 2002). Cytotoxic (Killer) T cells (TC cells) generally 
eradicate other cells of the body that are infected with intracellular pathogens and have 
been shown to play a similar role against cancerous cells (Alberts Bruce et al. 2002). 
Killer T cells are additionally known as CD8+ T cells due to expression of CD8 
glycoprotein on their surface. Memory T cells (Tmem cells) function as part of the long-
lived immunologic memory and serve to recognize cognate antigen in order to facilitate a 
rapid response to repeat infections (Alberts Bruce et al. 2002). The last T cell type, the T 
regulatory cells (Treg cells) play a number of hotly debated roles that typically revolve 
around maintaining immunologic tolerance. 
To prohibit immunopathology and fine-tune the immune responses, the 
stimulatory activities of T cells must be counteracted by suppressive mechanisms. Tregs 
are pivotal in this regard and act to suppress the potentially deleterious activities of other 
T cells (Fig. 1.3). About a dozen non-exclusive functions of Tregs have been 
characterized (Corthay A  2009). However, the most significant roles to mention here are: 
prevention of autoimmune diseases by establishing and maintaining immunologic self-
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tolerance (Sakaguchi Shimon et al. 2011); regulation of the effector class of the immune 
response (Fig. 1.3) (Matzinger Polly  2007), (Grant Charlotte R et al. 2015); and 
suppression of T cell activation triggered by weak stimuli (Baecher-Allan Clare et al. 
2002). A multitude of mechanisms have been reported by which Tregs perform these 
suppressive functions (Fig. 1.3A) (Sojka Dorothy K et al. 2008), (Grant Charlotte R et al. 
2015). Interestingly, however, many of the mechanisms by which T regulatory cells 
prevent forms of autoimmunity appear to be induced in an antigen-specific manner 
(Corthay A  2009).  
In vitro studies have demonstrated that Tregs must be activated via the T cell 
receptor (TCR) in order to become suppressive (Takahashi T et al. 1998), (Thornton A M 
et al. 1998). In vivo experiments appear to corroborate this conclusion, showing that the 
proliferation of Tregs in lymph nodes is antigen-dependent (Yamazaki Sayuri et al. 
2003). Taken together, such results suggest that suppression mediated by T regulatory 
cells is highly antigen-dependent. However, there are outstanding questions being raised 
as to whether the effector cells being regulated must be specific to the same antigen as the 
Tregs that suppress them.  
The induced functionality of Tregs in an antigen-specific manner appears 
especially efficacious regarding the prevention of autoimmune diseases. Experiments in 
the experimental autoimmune encephalomyelitis (EAE) mouse model, a model for 
multiple sclerosis, have shown that protection from the disease required the presence of 
myelin basic protein (MBP)-specific Tregs (Hori Shohei et al. 2002). Further, in the non-
obese diabetic (NOD) mouse model for type 1 diabetes, pancreatic autoantigen-specific 
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Tregs have been shown to be significantly more efficient than their polyclonal 
counterparts at preventing diabetes (Tang Qizhi et al. 2004), (Tarbell K V  2004). It has 
also been shown that pancreas-specific Tregs are only able to prevent diabetes when the 
Treg antigen was present, in vivo, in the pancreas itself (Tonkin Daniel R et al. 2008). 
Ultimately, such findings have opened a large field of investigation into the efficacy of 
autoantigen vaccinations to prevent or ameliorate autoimmune diseases via generation of 
antigen-specific Tregs. 
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Figure 1.3: Representation T Regulatory Cell Functions. (A) Four basic Treg mechanisms of 
suppression. (Left) Antigen presenting cell (APC) interaction with CTLA4 expressed on Tregs 
leads to CD80/CD86 costimulatory molecule down-regulation and inhibits the antigen 
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presentation to T effector cells. (Center) Interactions between Gal-9 on Tregs and TIM-3 on the 
surface of Teff induce the release of granzymes, which enter the Teff via perforin pores and 
induce apoptosis. (Right) Tregs produce anti-inflammatory cytokines TGFβ, IL-10, and IL-35. 
(Bottom) Tregs express ecto-enzymes on their surface (CD-39 and CD-73) that hydrolyze pro-
inflammatory ATP, splitting it into three molecules of adenosine. (B) Treg function in healthy vs 
autoimmune individuals. (Left) In healthy individuals Tregs suppress function of autoreactive 
Teff. (Right) Tregs fail to suppress autoreactive effector function, leading to the death of healthy 
organ tissue. Such failure is can be attributed to low Treg number, inhibited suppressive function, 
Treg conversion into Teff, and Teff resistance to Treg-mediated suppression. Figure is adapted 
from Grant Charlotte R et al. 2015.       
 
1.4 anti-IL-7Rα 
T cells use distinct genetic programs to conduct the development of lineage 
subsets and engender multiple effector functions. T cells specifically require T cell 
receptor (TCR)-mediated antigen signaling and signaling through costimulatory 
molecules as well as responses to chemokines, cytokines, small molecules, and 
metabolites in order to direct these genetic programs (Morris Gerald P et al. 2012). One 
of the factors that makes T cells unique is that they almost entirely depend on signals 
from TCR-mediated antigen recognition together with cytokine signaling just to stay 
alive and proliferate (Morris Gerald P et al. 2012). When the TCR detects a pathogen via 
binding or processed antigen presented by the major histocompatibility complex (MHC), 
cytokines are required to determine the magnitude and type of response to TCR 
stimulation. For example, signaling from interleukin-2 (IL-2) is indispensable in order to 
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retain effector and regulatory T cells (Barron Luke et al. 2010), (Dooms Hans et al. 
2004), (Smith K. A 1988). Further, integrated signaling from interleukin-15 (IL-15) 
(Lodolce J P et al. 1998) and interleukin-21 (IL-21) appear to be essential for the survival 
and function of CD4+ and CD8+ effector/memory T cells (Nurieva Roza et al. 2007), 
(Dooms Hans  2013).   
Interleukin-7 (IL-7) has been shown to play an important role in the development 
of T cells in the thymus (as well as B cells in the bone marrow) (Porter B O et al. 2000). 
However, the best characterized function of IL-7 are its signalling properties outside of 
the thymus. T cells outside of the thymus require tonic TCR signaing to survive. In the 
absence of antigen, this is thought to be achieved via weak interactions with self-
peptide/MHC ligands (Viret C et al. 1999). It has been shown, however, that this weak 
stimulation must be supported by IL-7 signaling in order for naive and memory T cell 
survival (Tan J T et al. 2001), (Rathmell J C et al. 2001). Additionally, IL-7 signaling has 
been shown to promote glucose metabolism through upregulation of the glucose 
transporter GLUT1 (Frauwirth Kenneth A et al. 2002), (Wofford J A et al. 2007). 
Further, the mode of metabolism used has been shown to modulate naive T cell fate by 
influencing the frequency of differentiation into either effector or regulatory subsets 
(Delgoffe Greg M et al. 2009), (Michalek Ryan D et al. 2011). Lastly, studies using IL-7 
cytokine as a treatment for anti-tumor and antiviral therapies unexpectedly revealed 
enhanced cytotoxic T cell activity and increased resistance to Treg-mediated suppression 
(Pellegrini Marc et al. 2011). It was shown that CD8+ cytotoxic T cells that are 
chronically exposed to the virus become exhausted and reduce their effector functions. 
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However, administering IL-7 caused the exhausted memory cell subset to regain its 
effector functions and clear the viral pathogen. This, in part, helped open a large field of 
investigation into the roles that IL-7 may play in autoimmunity due to similarities in 
prolonged exposure to antigen that may also result in effector T cell exhaustion.  
This investigation began with strong evidence from genome-wide association 
studies (GWAS) that identified risk-associated polymorphisms in IL-7Rα, the IL-7 
receptor, among patients with varying autoimmune diseases (Gregory Simon G et al. 
2007), (Lundmark Frida et al. 2007), (Todd John A et al. 2007). A litany of functional 
studies performed in both mice further highlighted the importance of IL-7Rα in 
autoimmune diseases such as multiple sclerosis (Lee Li-Fen et al. 2011), rheumatoid 
arthritis (Hartgring Sarita A Y et al. 2010), Sjogren's syndrome (Jin Jun-O et al. 2013), 
inflammatory bowel disease (Okada Eriko et al. 2005), systemic lupus erythematosus 
(Gonzalez-Quintial Rosana et al. 2011), and type 1 diabetes (Penaranda Cristina et al. 
2012).   
Recent studies investigating the role of IL-7 in type 1 diabetes have shown that 
passive immunization with anti-IL-7Rɑ antibodies can prevent disease onset in pre-
diabetic non-obese diabetic (NOD) mice and will even reverse the disease in new-onset 
diabetic mice (Penaranda Cristina et al. 2012), (Lee Li-Fen et al. 2012). Both studies 
offered explanations of the therapeutic effects of the treatment based on a shift in the 
proportion of Tregs to T effector/memory cells, favoring Tregs. Tregs, which have low 
levels of IL-7Rɑ expression, were thought to be less sensitive to the IL-7Rɑ blockade 
(Penaranda Cristina et al. 2012), (Lee Li-Fen et al. 2012).  One major drawback found in 
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these studies, however, is the requirement of prolonged treatment with anti-IL-7Rɑ 
monoclonal antibodies (mAbs) to induce a therapeutic effect, creating unease about 
inducing chronic immunosuppression in patients. Nonetheless, such promising results in 
mice have led many to hold high hopes for the utilization anti-IL-7Rɑ mAbs as a therapy 
for type 1 diabetes.   
 
1.5 Autoantigen Therapies  
Antigen-specific approaches to autoimmune disease therapies are a frequently 
cited alternative to broadly immunosuppressive methods because of their potential to 
provide specific inhibition of the pathological immune response without causing 
sweeping immunosuppression. Multiple antigen-specific treatments have been shown to 
be efficacious in disease prevention and reversal in non-obese diabetic (NOD) mice 
(Shoda Lisl K.M et al. 2005). Further, in human patients, efforts to deliver B-cell 
antigens as immunotherapeutic agents against T1D are currently underway (Leonard C. 
Harrison et al. 2013). The overarching goal of these studies is to induce an adaptive 
immune response that precisely targets the disease-causing islet-specific T cells in the 
hopes that this will inhibit their pathogenic activity.  
Studies performed between 1975 and 1991 investigating the antibody repertoires 
of T1D patients ultimately led to the identification of three major islet autoantibody 
specificities targeted against insulin, glutamic acid decarboxylase (GAD), and islet 
tyrosine phosphatase (Baekkeskov S et al. 1990), (Palmer J P et al. 1983), (Payton M A et 
al. 1995). Meaning that antibody-producing B cells were recognizing these particular 
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self-peptides as foreign antigen and producing a coordinated immune attack against them. 
The identification of such prevalent autoantigens in T1D patients prompted attempts by 
many groups to inhibit disease progression by tolerizing autoantigen-reactive T cells. 
Naturally, most T1D T cell epitope studies have focused on these three autoantigens. 
Largely due to the fact that class switched IgG autoantibodies against these islet proteins 
had strongly implied T cell help (Di Lorenzo T P et al. 2007).   
One of the earliest identified autoantigens in type 1 diabetes, glutamic acid 
decarboxylase (particularly the 65-kD isoform GAD65), was shown to have efficacy in 
preventing both insulitis and diabetes in NOD mice immunized with the epitope 
(Kaufman D L et al. 1993), (Ramiya V K et al. 1997), (Tisch R et al. 1999). In such 
studies, the protective effects of immunization with the GAD65 autoantigen were 
attributed largely to antigen-specific regulation of pathogenic Teffs by nonpathogenic 
Tregs (Tisch R et al. 1999).Despite its promise in mice, therapies using GAD65 
autoantigen immunization have been examined in a number of clinical trials with 
disappointing results (Ludvigsson Johnny et al. 2012), (Wherrett Diane K. et al. 2011).  
In other clinical trials, autoantigen GAD65 in solution with the adjuvant alum was 
used to modulate the pathogenic Th1 response to a Th2 response and potentially expand 
Tregs (Pihl M. et al. 2013) (Axelsson S. et al. 2012). Disappointingly, antigen-specific 
immunotherapies have largely failed to achieve long-lasting disease prevention or 
remission in T1D patients. However, the promise of tolerizing the immune system by 
generating antigen-specific Tregs in T1D patients remains a promising method for the 
development efficacious therapies to autoimmune diseases. Thus, a combination of 
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autoantigen therapies with an additional modulator of the T cell response may yield an 
effective strategy to achieve positive results.   
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CHAPTER 2: MATERIALS AND METHODS  
 
Segments of this chapter have been adapted from Vasques-Mateo et al. 2019 
 
2.1 Mice  
 Non-obese diabetic (NOD) mice used for experimentation were females, aged ~9-
13 weeks that were either purchased from The Jackson Laboratory or bred at the Boston 
University Medical Campus (BUMC) under specific pathogen-free conditions under a 12 
hour light/dark cycle. All mice had free access to water and standard mouse chow (NIH 
approved diet) within sterilized plastic cages. All studies were performed with stringent 
adherence to recommendations in the Guide for Care and Use of Laboratory Animals of 
the National Institutes of Health. Our protocol was approved by the Institutional Animal 
Care and Use Committee (IACUC) of the Boston University Medical Campus.    
 
2.2 Immunizations with alum 
For in vivo experiments involving the adjuvant alum, mice were randomly 
assigned to control and treatment groups by cage number. Mice were immunized with 10 
µg of islet peptide BDC2.5 mimotope (RTRPLWVRME) mixed formulated Alum (100 
µl, in 100 µl of PBS) (ThermoScientific, USA) via intraperitoneal injection on day 0. 
Mice were then treated with 0.5 mg of anti-IL-7Rα or IgG antibodies intraperitoneally on 
days 0 and 4. Spleens and peripheral lymph nodes (PLN) were harvested on day 7 for 
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lymphocyte isolation, ELISPOT assay, magnetic enrichment of antigen-specific cells, and 
staining for flow cytometry.  
 
2.3 Islet peptide-KLH conjugation and immunization  
Islet peptide conjugation to keyhole limpet haemocyanin (KLH) was achieved 
using the Imject EDC mcKLH spin kit (Thermo Fisher) with strict adherence to the 
manufacturer’s protocol. The four islet peptides (WE14 or BDC2.5 mimotope, InsB(9-
23), GAD65(524-543) (SRLSKVAPVIKARMMEYGTT), and IGRP(206-214) 
(VYLKTNVFL)) were mixed in equal amounts. Then the mix was combined in a 1:1 
ratio with mariculture KLH (Imject mcKLH, Thermo Fisher) in EDC conjugation buffer 
and 15% DMSO. 2.5 mg of EDC crosslinker (1-ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride) was added to the peptide-KLH EDC 
buffer mixture. The reaction was incubated on a rocking shaker for 2 hours at room 
temperature to allow EDC to link carboxyl and amino groups between the peptides and 
KLH. Following the manufacturer's recommendation, the conjugate solution is desalted 
using spin columns included in the kit. To ensure no any immunogenic activity observed 
was the result of Ag-KLH conjugate and not solution contaminants, the solution was 
further purified via sterile filtration. Ag-KLH concentrations were quantified using a 
Nanodrop and diluted in PBS to achieve the desired concentrations (3-350 µg/ 100 µL). 
100 µL of the islet Ag-KLH solution was administered via intravenous injection on day 
0, followed by Anti-IL-7Rα or rat IgG antibodies (0.5 mg) administered intraperitoneally 
the same day. Intraperitoneal injections of Anti-IL-7Rα or rat IgG antibodies (0.5 mg) 
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were repeated on day 4. Spleens and peripheral lymph nodes (PLN) were harvested on 
day 7 for lymphocyte isolation, ELISPOT assay, magnetic enrichment of antigen-specific 
cells, and staining for flow cytometry.  
 
2.4 Splenocyte isolation  
After dissection, spleens and PLNs of mice were forced through a 40 µm into a 
PBS+2% FBS buffer. Cells were washed with this buffer and pelleted by centrifugation. 
Cell pellets were resuspended in 1 mL of ammonium-chloride-potassium (ACK) lysing 
buffer (Thermo Fisher) to lyse red blood cells in solution with the splenocytes. Then, the 
suspension was washed with phosphate buffered saline (PBS) to ensure lysis did not 
continue before being counted and aliquoted for use in magnetic enrichment of antigen-
specific cells, staining for flow cytometry, and ELISPOT assay.    
 
2.5 Magnetic enrichment of antigen-specific T cells and tetramer detection  
Characterization of islet peptide specific T cells was achieved using a magnetic 
enrichment protocol using pooled samples of lymphocytes isolated from PLNs and 
spleens of experimental mice. Following isolation, lymphocyte suspensions were 
incubated with Fc block (anti-CD16/CD32 antibodies)to inhibit non-specific binding of 
antibodies used later for flow cytometry. After washing away excess Fc block with PBS 
+ 2% fetal bovine serum (FBS) buffer, PE-labeled BDC2.5 (peptide sequence: 
RTRPLWVRME; National Institutes of Health tetramer core facility) that will be bound 
by antigen-specific cells was added to the lymphocyte suspension and allowed to 
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incubate on a rocking shaker for 1 hour at room temperature. The cells were then washed 
3X using a PBS + 2% FBS buffer to remove unbound PE-BDC2.5. Anti-PE microbeads 
(Miltenyi Biotech, Germany) were then added in excess and incubated for 30 minutes at 
4 C, washed with 15 mL of PBS+2% FBS+2mM EDTA buffer, and passed through a 
magnetic column. To collect antigen-specific cells, the column was removed from the 
magnet and cells were eluted using the PBS+2% FBS+2mM EDTA buffer. Samples were 
then used in the antibody staining for flow cytometry.      
 
2.6 Antibody staining for flow cytometry  
Following magnetic enrichment, cells were incubated with a Fixable Viability 
Dye (eBioscience, US) and incubated for 15 minutes at 4oC to distinguish living cells 
from dead during flow cytometry analysis. Cells were washed using PBS + 2% FBS 
buffer and combined with a master mix containing the antibodies used for phenotyping of 
T cells: anti-CD4 (RM4-5), anti-CD25 (PC61.5), anti-CD44 (IM7), anti-Foxp3 (FJK-
16s), anti-CD11b (M1/70), anti-CD11c (N418), anti-B220 (RA3-6B2) (eBioscience, 
Biolegend or BD Pharmingen, US). Extracellular staining was performed by incubation 
at 4oC for 30 minutes. Intracellular staining for FoxP3 was performed after cells were 
fixed and permeabilized using a FoxP3 staining buffer set (eBioscience) as per 
manufacturer’s instructions. All antibodies were utilized at a 1/100 dilution, with the 
exception of anti-CD44 which required a 1/400 dilution due to abundant expression. 
Finally, counting beads were added for accurate cell number quantification (123count 
eBeads, eBioscience, USA).          
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2.7 Flow cytometry  
Both the tetramer staining and phenotypic markers observed within cell 
populations were analyzed by multiparameter flow cytometry using an LSRII flow 
cytometer (BD Biosciences). Data generated via flow cytometry were analyzed with 
FlowJo software. The total numbers of tetramer-positive cells in each sample were 
calculated as follows: (event count in tetramer+ gate/event count in eBeads gate) x the 
total number of eBeads per sample.  
 
2.8 ELISPOT assay  
  96-well MultiScreen filter plates (Merck Millipore, USA) were coated with 5 g/ml 
capture antibodies for anti-IL-2, anti-IL-10 or anti-IFN-γ (MABTECH, Sweden) and 
incubated overnight at 4°C. Following multiple washes with PBS, 1x106 cells per well 
from pooled spleen and PLN samples were added and incubated overnight at 37°C, in the 
presence or absence of 0.1 µM of BDC2.5 peptide. Cells were removed and the plates 
washed with PBS. 1 µg/ml biotinylated anti-IL-2, anti-IL-10 or anti-IFN-γ detection 
antibodies (MABTECH) were then added and allowed to incubate for 1 hour at room 
temperature. Plates were again washed to remove detection antibodies followed by the 
addition of streptavidin-conjugated alkaline phosphatase (Jackson ImmunoResearch, 
USA) and incubated for 1 hour at 4°C. Vector Blue AP substrate (Vector Laboratories, 
USA) incubated for ~10 minutes at room temperature was then used reveal spots for 
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quantification. The number of spots was calculated using an ImmunoSpot analyzer and 
included software (ImmunoSpot, USA).    
 
2.9 Disease monitoring for prevention experiments   
Diabetes incidence was followed weekly by urine analysis with Diastix strips as 
well as blood glucose measurements using a Contour glucose meter (Bayer, USA). 
Diabetes incidences were characterized by blood glucose levels >250 mg/dL. The 
percentage of diabetic mice was calculated using the Kaplan-Meier survival curves 
method. 
 
2.10 Histology  
Histological analysis was performed by fixing pancreata in 10% (vol/vol) 
buffered formalin and staining 5-m paraffin-embedded tissue sections with hematoxylin 
& eosin (H&E); 10 sections per pancreas were blindly scored for insulitis using an 
Olympus BH-2 microscope. Scores are as follows: 0 = no infiltrate, 1 = 0-25%, 2 = 25-
75%, 3 = > 75%. Images were captured with a Micropublisher 5.0 RTV digital camera (Q 
Imaging).  
 
 2.11 Statistics  
Statistically significant differences between groups were determined with one- or 
two-tailed unpaired or paired t tests or with one-way ANOVA with Bonferroni’s multiple 
comparison test (ELISPOT assays), using GraphPad Prism. P values≤0.05 were 
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considered significant. Horizontal lines in graphs indicate statistical significance 
(*=p≤0.05, **=p≤0.005, 172 ***=p≤0.0005, ns=p>0.05). For diabetes incidence studies, 
significance was determined using the Mantel-Cox log-rank test. 
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CHAPTER 3: RESULTS 
 
Segments of this chapter were previously published in Vasques-Mateo et al. 2019. 
Portions of this chapter were performed by Christina Vasquez-Mateo (Figures 3.2E & 
3.4), Justin Collins (Figure 3.2E), and Sarah J. Goldberg (Figure 3.4). All other sections 
were performed or contain data by Maxx Lawson.  
 
3.1 Alum-formulated islet autoantigen immunization with anti-IL-7Rɑ blockade 
diminishes diabetogenic T cells but enhances non-specific cytokine production    
 
Previous clinical trials attempting to vaccinate recent-onset type-1 diabetes (T1D) 
patients with GAD65, an islet-autoantigen, displayed only short-lived stabilization of c-
peptide levels (Ludvigsson Johnny et al. 2012), (Wherrett Diane K. et al. 2011). Other 
studies, performed in mice, had discovered that an IL-7 receptor blockade prevented 
autoimmune diabetes by promoting the inhibition of effector and memory T cell 
populations (Penaranda Cristina et al. 2012). These findings prompted an investigation as 
to whether combining autoantigen vaccinations with an additional immune modulator 
(anti-IL-7Rɑ) could boost the efficacy of the induced anti-islet T cell response by biasing 
it towards regulatory functions and away from effector functions.  
In order to analyze the effects that anti-IL-7Rɑ treatment had on the antigen-
specific T cell population in vivo, we had immunized pre-diabetic non-obese diabetic 
(NOD) mice with BDC2.5 mimotope formulated with alum (day 0) in conjunction with 
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anti-IL-7Rɑ or an IgG control immunization (day 4) (Fig. 3.2A). BDC2.5-TCR 
expressing T cells are a well characterized diabetogenic T cell population found in the 
NOD mouse model (You, et al. 2003). The BDC2.5 mimotope is commonly used to 
stimulate this population of cells in an autoantigen-specific manner and has been shown 
to significantly increase the population of Tregs in NOD mice (Hu Chang-yun et al. 
2007). Peripheral lymph nodes (PLN) and spleens of immunized mice were then 
harvested 7 days after initial islet-peptide immunization. Following organ harvest, a 
single-cell suspension was prepared and pooled by treatment condition. The isolated cells 
were then counted using a hemocytometer and fractions taken for either magnetic 
enrichment or ELISPOT assay.  
For those fractions used in the magnetic enrichment, the population of BDC2.5-
specific T cell was enhanced using PE-labeled BDC2.5 tetramer and anti-PE affixed to 
magnetic MicroBeads. These were then run over a magnetic column wherein the 
BDC2.5-specific cells would bind the column and, later, be eluted (see chapter 2: 
Materials and Methods). After incubation with a Fixable Viability Dye, to distinguish 
live cells from dead (live/dead), the column eluent was stained using antibodies against 
CD4, CD25, CD44, Foxp3, CD11b, CD11c, and B220 before being analyzed via flow 
cytometry. Cells that exhibited the live/dead dye or that displayed expression of CD11b, 
CD11c, and B220 were considered irrelevant for our analyses and removed via gating 
(Fig. 1). Antigen-specific T cells were considered those that did not meet these exclusion 
criteria and that were highly positive for the PE-labeled BDC2.5 antibody.   
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Figure 3.1: Representative Gating Strategy to Identify Antigen-specific CD4+ T Cells. This figure 
exhibits the gating strategy used to identify and characterize the islet-peptide specific T cells from 
immunized mice. (Top left) Forward and side scatter used to exclude clumped cells and debris from 
analyses. (Top right) Living CD4+ cells. (Bottom left) Exclusion of CD11b, CD11c, and B220 expressing 
cells from CD4+ population. (Bottom right) Representative gating for CD44 activation marker and 
BDC2.5-specific T cell detection.   
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 Our results indicated that immunization with the BDC2.5 mimotope was 
successful in activating the T cell population, as shown by sizable increases in CD44 
activation marker expression among both IgG and anti-IL-7Rɑ treated groups (Fig. 3.2B). 
Thus, blocking IL-7Rɑ during immunization did not inhibit T cell activation. However, a 
comparison between IgG and anti-IL-7Rɑ treated mice revealed a reduction in the total 
number of recovered BDC2.5 T cells in mice that underwent the IL-Rɑ blockade (Fig. 
3.2C). Meaning that treatment with anti-IL-7Rɑ reduced the total number of antigen-
specific T cells, but not due to restrictions in T cell activation. Surprisingly, both IgG and 
anti-IL-7Rɑ treated groups displayed sparse populations of FoxP3+ T regulatory cells 
(Fig. 3.2D). This finding is noteworthy as it contrasts with what has been suggested by 
other mouse studies using autoantigens and alum (Boettler Tobias et al. 2013).  
 The fractions of suspended cells, taken from PLN and spleen harvest, that were 
not utilized in the flow cytometry analyses were used for an ELISPOT assay. The 
ELISPOT assays and the data they gave rise to were performed and analyzed by Christina 
Vasquez-Mateo and Justin Collins. Plates were coated with anti-IL-2, anti-IL10, and anti-
IFN-! capture antibodies. Once coated, pooled cell fractions were added to the wells both 
in the presence and absence of BDC2.5 peptide and allowed to incubate overnight. 
Cytokine production by these cells was then revealed via addition of biotinylated anti-IL-
2, anti-IL10, and anti-IFN-! antibodies. The wells were then incubated with streptavidin 
alkaline phosphatase to create spots where cells had produced cytokine. The spots formed 
by cytokine-producing effector cells were then counted using an ImmunoSpot analyzer.  
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 ELISPOT analyses revealed increased IL-2, IL-10, and IFN-	! production by T 
effector cells in mice treated with anti-IL-7Rɑ when compared to the IgG-treated cohort 
(Fig. 3.2E, data by Christina Vasquez-Mateo & Justin Collins). No significant changes in 
IL-10 or IFN-! production were detected between wells stimulated with BDC2.5 peptide 
ex vivo when compared to their unstimulated counterparts (Fig. 3.2E, data by Christina 
Vasquez-Mateo & Justin Collins). The limited inducibility of cytokine-producing T 
effector cells in the presence of BDC2.5 peptide, together with the previously highlighted 
reductions in BDC2.5-specific T cells (Fig. 3.2C), appear to suggest that non-antigen-
specific bystander immune cells are the source of enhanced cytokine secretion in mice 
treated with anti-IL-7Rɑ.  
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Figure 3.2: Islet Antigen and Alum Fail to Increase Antigen-specific Treg Population in Mice Treated 
with anti-IL7Rɑ. (A) Experiment timeline. 9-week old female prediabetic NOD mice were immunized 
with alum-formulated BDC2.5 mimotope and treated with anti-IL-7Rα or rat IgG antibodies on days 0 and 
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4. Pancreatic lymph nodes, peripheral lymph nodes, and spleen were harvested and analyzed via flow 
cytometry. Cytokine-producing cells were quantified via ELISPOT assays. (see chapter 2: Materials and 
Methods) (B) Representative dot plots display CD44 expression on BDC2.5+ cells and bystander CD4+ T 
cells. (C) Displays the absolute numbers of BDC2.5+ T cells present in individual mice from three separate 
experiments ± SD (n=6 or 7). (D) Representative dot plots showing Foxp3 and CD25 expression within the 
BDC2.5 tetramer+ T cell gate. (E) Displays the number of spots resulting from the ELISPOT assays both 
stimulated with BDC2.5 peptide, in vitro (closed symbols) and unstimulated (open symbols) (n=3) . 
Unpaired t-test (C) and ANOVA with Bonferroni’s posttest (E) were used for statistical analysis, 
**represents p≤0.005, ***represents p≤0.0005 
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3.2 Islet antigen conjugated to KLH increases Treg population irrespective of IL-
7Rɑ blockade 
 
 Keyhole limpet haemocyanin (KLH) is a large protein produced by Megathura 
crenulata that is known to be a potent immunoactivator and has been shown to pose little 
risk of adverse immune responses in humans (Harris J R et al. 1999). KLH is widely used 
as a carrier protein for antigens because of its size, immunogenicity, and well-
characterized methods for hapten coupling (Harris J R et al. 1999). Haptens are relatively 
small molecules that require conjugation to a substantially larger carrier in order to evoke 
an immune response. The immunologically useful properties of KLH have spurred a 
large body of research on the molecule that paint an encouraging picture for its use in 
future autoantigen vaccines. In fact, autoantigen haptens conjugated to KLH have 
previously been examined for use as a vaccine against numerous cancer types including 
non-Hodgkin's lymphoma, breast cancer, cutaneous melanoma, and bladder cancer, with 
promising results (Miles David et al. 2011), (Melero Ignacio et al. 2014). 
 Our lab decided to analyze whether the previously characterized responses to islet 
autoantigen conjugated to KLH could be modulated towards the induction of antigen-
specific T regulatory cells via addition of anti-IL-7Rɑ monoclonal antibodies (mAbs). To 
do so, we conjugated five previously characterized islet autoantigens (BDC2.5 mimotope, 
GAD65, Insulin B, and IGRP) to KLH and immunized pre-diabetic NOD mice with 350 
µg of antigen-KLH conjugate (Ag-KLH) or an unconjugated KLH control (175 µg). 
These mice were co-treated with either anti-IL-7Rɑ mAbs or rat IgG as a control. 
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Peripheral lymph nodes and spleens were then harvested 8 days after immunization 
where they were treated to the same magnetic enrichment and ELISPOT procedures 
described previously (see page 21).  Contrary our results immunizing with unconjugated 
BDC2.5 and alum (see page 27), islet Ag-KLH had increased the number of FoxP3+ 
antigen-specific Tregs significantly (Fig. 3.4A & B, data by Christina Vasquez-Mateo & 
Sarah J. Goldberg). However, no significant differences in the population of FoxP3+ 
Tregs were observed between IgG and anti-IL-7Rɑ treated mice that received the Ag-
KLH immunization (Fig. 3.4B, data by Christina Vasquez-Mateo & Sarah J. Goldberg). 
To investigate these findings further, our lab performed a dose response experiment 
utilizing 3, 30, and 300 µg of Ag-KLH in the presence or absence of anti-IL-7Rɑ (Fig. 
3.4C & D, data by Christina Vasquez-Mateo & Sarah J. Goldberg). These experiments 
revealed that, similarly to the BDC2.5+alum experiments, anti-IL-7Rɑ co-treatment 
reduced the number of antigen-specific T cells at 30 and 300 µg of Ag-KLH (Fig. 3.4C), 
but did not reduce the proportion of FoxP3+ Tregs found (Fig. 3.4D, data by Christina 
Vasquez-Mateo & Sarah J. Goldberg). ELISPOT assays revealed that, similarly to the 
BDC2.5+alum experiments, IL-7Rɑ blockade increased cytokine production irrespective 
of immunization with Ag-KLH or KLH alone (Fig. 3.4E & F data by Christina Vasquez-
Mateo & Sarah J. Goldberg). Taken together, these results appear to substantiate our 
findings (see page 28) that anti-IL-7Rɑ mAbs augment cytokine production by non-
specific bystander T cells during autoantigen co-treatment.    
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Figure 3.4: Anti-IL-7Rα mAbs promote cytokine production but not antigen-specific Tregs 
300 after islet Ag-KLH immunization. Islet Ag-KLH or KLH immunization with anti-IL-7Rα 
antibodies or rat IgG co-treatment administered on days 0 and 4 as in Fig 3.2. In 11-13 week old 
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NOD mice (A) Contour plots display FoxP3 and CD25 expressing cells within a CD4+BDC2.5+ 
population. (B) Displays the proportions of the FoxP3+ Tregs within the BDC2.5+ population 
(n=3). (C) Bar graph exhibits absolute numbers of BDC2.5+ T cells from individual mice on day 
7 after immunization with 3, 30, or 300 µg of Ag-KLH ± SD (n=3). (D) Bar graph exhibits the 
proportion of FoxP3+ Tregs as in B. (E & F) Displays the number of spots resulting from the 
ELISPOT assays both stimulated, in vitro, with a mixture of islet autoantigens used for 
immunization as well as unstimulated controls (open symbols) (n=3). ANOVA with Bonferroni’s 
post test were used for statistical analysis, **represents p≤0.005, *** represents p≤0.0005 
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3.3 Vaccination with Conjugated Islet Ag-KLH Delays T1D Onset in NOD Mice 
 
 Previous studies wherein NOD mice were immunized with islet autoantigen 
(GAD65) and alum have failed to prevent T1D disease onset when compared to placebo 
controls (Boettler Tobias et al. 2013). Such studies have also reported that treatments 
with islet autoantigens and alum result in an expanded population of T regulatory cells, 
with no direct evidence that the expanded population consisted of antigen-specific cells. 
Our lab reports similar findings with regards to T1D onset when immunizing with islet 
autoantigen (BDC2.5) and alum (data not shown) (Vasquez-mateo et al. 2019). However, 
we have shown directly that islet autoantigen peptide and alum alone do not enhance 
Tregs and do not skew towards a regulatory phenotype (Fig. 3.2).   
However, our findings have indeed suggested that immunizations with islet 
autoantigens (BDC2.5 mimotope, GAD65, Insulin B, and IGRP) conjugated to KLH 
produce a large proportion of T regulatory cells (Fig. 3.4B). Expansion of Treg 
populations that inhibit effector function have previously been shown to be the 
mechanism by which IL-7Rɑ blockade protects against T1D onset in prevention studies 
of NOD mice (Penaranda Cristina et al. 2012).  
Thus, questions were raised as to the therapeutic potential of the Ag-KLH 
vaccination method for type-1-diabetes. In order to examine this possibility, a prevention 
study was performed wherein two groups of NOD mice were immunized with islet Ag-
KLH and co-treated with either anti-IL-7Rɑ (n=10) or rat IgG (n=10). T1D disease onset 
was followed for 34 weeks via urine analysis and monitoring of blood glucose levels. 
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Interestingly, islet Ag-KLH immunization appeared to delay and in some cases even 
prevent the onset of T1D when compared to untreated mice (Fig. 3.5A). This finding was 
in direct contrast to prevention studies performed previously by our lab that suggested no 
delay in T1D onset in mice treated with islet peptide (BDC2.5) and alum (data not 
shown) (Vasquez-mateo et al. 2019). Importantly, anti-IL-7Rɑ mAb co-treatment seemed 
to impede the protective effect of Ag-KLH treatment (Fig. 3.5A). Given our previous 
findings that anti-IL-7Rɑ mAbs augment cytokine production by non-specific bystander 
T cells during autoantigen co-treatment (Fig. 3.2E, 3.4E & F), it is plausible that 
inordinate production of pro-inflammatory cytokines by these cells inhibits the protective 
effects of Ag-KLH immunization against T1D.   
These findings warranted an investigation into the differences between IgG and 
anti-IL-7Rɑ co-treated animals from Ag-KLH immunization experiments. Histological 
analyses were performed on the pancreata of Ag-KLH immunized NOD mice. These 
organs were formalin fixed and embedded in paraffin for sectioning before undergoing 
haemotoxylin and eosin (H&E) staining. Sections were then blindly scored for insulitis, 
characterized by lesions with clear islet infiltration of lymphoid cells (0=no infiltrate, 
1=0-25%, 2=25-75%, and 3=>75%) (Fig. 3.5B & C). Surprisingly, histological analyses 
of islet infiltration displayed no significant differences in the number of insulitic islets 
between IgG and anti-IL-7Rɑ treated mice (Fig. 3.5B & C). However, anti-IL-7Rɑ 
treated mice did display a trend towards more aggressive lymphoid cell infiltration per 
islet (Fig. 3.5B & C). 
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The encouraging protective effects of islet antigen conjugated KLH 
immunizations promote further investigation into Ag-KLH therapies as a vaccination 
method against autoimmune diseases. However, the loss of such protection and trend 
towards more severe autoimmune phenotypes appear to warn against the use of anti-IL-
7Rɑ co-treatment, likely due to inordinate pro-inflammatory cytokine production by non-
specific bystander T cells.       
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Figure 3.5: Vaccination with islet Ag-KLH delays T1D onset in NOD mice. 9 week old NOD mice were 
immunized with Iselt Ag-KLH and co-treated with either anti-IL-7Rα mAbs or IgG on days 4 and 8. Then 
followed for 43 weeks for diabetes onset. (A) Kaplan-Meier plot displays the proportion of diabetic mice as 
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a function of age within each immunization group (n=10) and in our untreated NOD colony (n=30). (B) 
Displays histological scoring of lymphoid cell infiltration in islets of Langerhans from Ag-KLH immunized 
NOD mice that were not diabetic at 43 weeks after H&E staining (rat IgG, n= 6; anti-IL-7R, n=5). (C) 
Displays representative images of the islets of Langerhans (red arrows) from the mice in B.  
.
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CHAPTER 4: DISCUSSION 
 
4.1 Discussion  
 In the experiments presented, we explored the feasibility of utilizing islet antigen 
vaccinations in conjunction with anti-IL-7Rɑ mAbs to modulate a T cell response and 
prevent type 1 diabetes. Our rationale was based largely on previous findings that anti-IL-
7Rɑ mAbs altered the balance of T regulatory and T conventional cells and had been 
shown to prevent and reverse T1D in NOD mice (Penaranda Cristina et al. 2012). 
However, the requirement for long-term treatment with anti-IL-7Rɑ mAbs in order to 
elicit the protective effects in the aforementioned study led us to seek alternative methods 
to induce protection due the likelihood of immunodeficiencies resulting from tonic IL-Rɑ 
blockade.  
A significant amount of investigations into autoantigen therapies to curb type 1 
diabetes had already been performed, with promising results (Kaufman D L et al. 1993), 
(Ramiya V K et al. 1997), (Tisch R et al. 1999). However, these treatments displayed 
only short-term alleviation from the disease in humans (Ludvigsson Johnny et al. 2012), 
(Wherrett Diane K. et al. 2011). It has previously been proposed that addition of an 
immunomodulatory factor may improve the effects of antigen-specific immunizations for 
T1D as well as other autoimmune diseases (Matthews J B et al. 2010).   
 We reasoned that islet antigen immunotherapy in conjunction with the short-term 
administration of anti-IL-7Rɑ mAbs may reduce the prevalence of diabetogenic effector 
and memory T cells, while increasing the prevalence of protective antigen-specific T 
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regulatory cells. Such reasoning carried the hopes of utilizing the immunomodulatory 
effects of anti-IL-7Rɑ mAbs while avoiding the immunodeficiencies of long-term 
treatment. While T regulatory cells have been shown to express low levels of IL-7Rɑ 
(Liu Weihong et al. 2006), effector/memory T cells displayed high levels of surface IL-
7Rɑ expression and largely depend on the cytokine for their survival (Tan J T et al. 
2001), (Rathmell J C et al. 2001). These differences in expression and function of IL-7Rɑ 
appeared to suggest that blocking the receptor may produce the desired 
immunomodulatory effects of reducing the effector/memory T cell subset while 
conserving Tregs.  
Our analysis of the antigen-specific T cell response after immunization with islet 
peptide (BDC2.5) and alum revealed no significant number of antigen-specific Tregs 
within the BDC2.5+ population. Further, this population was not increased in mice 
treated with the anti-IL-7Rɑ mAbs. Initially this finding appears to contrasts with 
vaccination studies using islet autoantigen GAD and alum in both humans and mice that 
report consistent increases in FoxP3+ Tregs (Boettler Tobias et al. 2013), (Hjorth Maria 
et al. 2011), (Pihl M et al. 2013). However, these studies do not show directly that the 
expanded Treg population is antigen-specific via tetramer staining and, instead, imply it 
via restimulation with GAD65 in vitro (Boettler Tobias et al. 2013), (Hjorth Maria et al. 
2011), (Pihl M et al. 2013). Further, a recently published study that had expanded 
GAD65-specific T cells from GAD-alum treated patients in vitro displayed no increased 
proportion of antigen-specific Tregs and no enhanced suppressive function (Pihl Mikael 
et al. 2017). Taken together, these findings appear to suggest that the expanded Treg 
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populations following restimulation in vitro documented previously are the result of an 
indirect effect on polyclonal Tregs.  
Our lab has proposed non-specific IL-2 production in T cells, that acts on 
bystander Tregs, as a candidate mechanism for such an effect (Vasques-Mateo et al. 
2019) (O'Gorman William E et al. 2009). IL-2 has been well characterized as an essential 
cytokine for the homeostasis and expansion of natural Tregs in the periphery as well as 
for the survival and function of induced Tregs (Katzman Shoshana D et al. 2011), (Wolf 
Martina et al. 2001), (Kramer S  1995). For example, depleting IL-2 or a IL-2Rɑ (CD25) 
blockade has been shown to result in the eradication of Tregs and the development of 
systemic autoimmunity (Setoguchi Ruka et al. 2005). We have shown that treatment with 
anti-IL-7Rɑ mAbs reliably induced IL-2 production in non-specific bystander T cells. 
This may explain the increased Treg populations reported in previous IL-7Rɑ blockade 
studies (Boettler Tobias et al. 2013), (Hjorth Maria et al. 2011), (Pihl M et al. 2013). 
Additionally, a recent study has reported that islet autoantigen-specific Tregs express 
significantly lower levels of CD25, the IL-2 receptor (IL-2Rɑ) (Hotta-Iwamura Chie et 
al. 2018). It is therefore plausible that the antigen-specific Tregs induced via 
immunization with islet-autoantigen are less susceptible to the IL-2 induced expansion 
observed. Though, significantly more work remains to be done investigating the 
relationship between IL-2 signaling and autoantigen-specific Tregs.    
Perhaps the most interesting finding we have shown from our study is that use of 
keyhole limpet haemocyanin (KLH) as a carrier for islet-autoantigen does expand 
antigen-specific Tregs within the tetramer+ population. Further, immunization with islet 
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Ag-KLH was observed to be protective against type 1 diabetes onset. These findings may 
indicate islet Ag-KLH as an auspicious delivery method for autoantigen vaccination. 
However, addition of the IL-7Rɑ blockade appears to subvert the protective effects of 
islet Ag-KLH immunization. Plausibly due to the excessive production of pro-
inflammatory cytokines observed across anti-IL-7Rɑ treated cohorts. In this regard, there 
are a couple of salient considerations to be made as reported in our lab’s most recent 
publication (Vasques-Mateo et al. 2019).  
First, the role of IL-7 with regards to Treg biology remains hotly debated. 
Independent studies have reported both positive and negative functions with little clear 
indications about how these opposing functions fit with one-another (Gratz Iris K et al. 
2013), (Li Cheng-Rui et al. 2011). Second, anti-IL-7Rɑ mAbs are currently being 
investigated against autoimmune diseases in clinical trials. We have shown that under 
certain circumstances treatments with anti-IL-7Rɑ mAbs will result in excessive cytokine 
production (IL-2, IL-10 and IFN-	!) and the potential risk to patient safety of these 
antibodies ought to be considered. Our lab and others have shown previously that long-
term treatment with these anti-IL-7Rɑ mAbs reduced cytokine-producing T cells 
(Penaranda Cristina et al. 2012), (Lee Li-Fen et al. 2012). However, it is plausible that the 
observed reduction in cytokine production may be preceded by excessive cytokine 
production early on (Vasques-Mateo et al. 2019). Therefore these finding may have 
significant consequences in the clinical development of IL-7Rɑ target against 
autoimmune diseases. 
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4.2 Open Questions and Future Directions 
 The study presented has opened inquiries into the potential effects of IL-2 
signaling on antigen-specific Tregs. Further, it has been questioned whether the 
expansion of non-specific Tregs shown in many other studies is the result of excess IL-2 
production induced by the IL-7Rɑ blockade (Boettler Tobias et al. 2013), (Hjorth Maria 
et al. 2011), (Pihl M et al. 2013). In order to investigate these observations, our lab has 
generated an S100a4Cre X IL-2flox mouse. S100a4 is a gene commonly known to play 
roles in the invasion of cancer cells (Garrett Sarah C et al. 2006). However, in T cells, it 
has been shown to be exclusively expressed by the effector/memory subset (Weatherly 
Kathleen et al. 2015). Thus, our lab plans to analyze mice treated with anti-IL-7Rɑ mAbs 
whose IL-2 production has been genetically inhibited in the effector/memory T cell 
subsets specifically. Differences in expansion between non-specific and autoantigen-
specific Tregs in such an experiment may inform the future of IL-7Rɑ based treatments 
for autoimmune diseases.  
It has been shown previously that regulatory T cells have the potential to lose 
their characteristic FoxP3 expression, become pathogenic and regain IL-2 expression 
(deemed exTregs) (Joller Nicole et al. 2014), (Guo Jitao et al. 2015), (Do Jeongsu et al. 
2017). Further, it has been shown that the risk of conversion to exTregs is exacerbated in 
autoimmune diseases (Guo Jitao et al. 2015). In light of these findings, it is pertinent to 
question whether autoantigen immunizations with anti-IL-7Rɑ mAbs generated islet 
peptide-specific Tregs that had subsequently lost FoxP3 expression and expanded non-
specific Treg populations by regaining IL-2 expression. In order to investigate this, a 
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FoxP3Cre X IL-2flox mouse has been generated by our lab that will restrict IL-2 
expression among exTregs. Overall, these future experiments are designed to better 
characterize the effects, and possible sources, of excess IL-2 production in anti-IL-7Rɑ 
treatment.  
 
4.3 Conclusion 
 Overall, blocking IL-7Rɑ via the administration of anti-IL-7Rɑ mAbs has the 
potential to modulate the T cell response to vaccination towards that of a more regulatory 
phenotype. However, questions have been raised as to whether the Tregs induced by this 
treatment have been largely non-specific to antigen. We have also shown that 
immunization with islet peptide (BDC2.5) and alum is a relatively poor inducer of 
autoantigen-specific Tregs that are thought to be important for protection from 
autoimmunity and may help explain disappointing results in clinical trials. However, islet 
Ag-KLH represents a highly promising delivery method to induce the desired regulatory 
response. Though, significant work still remains to determine whether there exists a 
combination of antigens, adjuvants, antibodies, and timing of immunization that could 
potentially avoid the negative side-effects observed and lead to the successful use of anti-
IL-7Rɑ mAbs in combination immunotherapy. 
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